Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Equities

002675

CNE100001DP5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
13.31 CNY +1.22% Intraday chart for Yantai Dongcheng Pharmaceutical Group Co.,Ltd. +7.69% -27.39%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug in Singapore MT
Dongcheng Pharmaceutical to Buy Liver Drug Rights from Affiliate for 85 Million Yuan MT
Dongcheng Pharmaceutical Unit to Buy Rights to Tumor-Detecting Drug for 63 Million Yuan; Shares Up 10% MT
Dongcheng Pharma's Singaporean Unit Gets FDA's Nod to Carry Out Trial on 68GaLNC1007 Injection MT
Yantai Dongcheng Pharma Unit Secures License for Radioactive Cargo Transport MT
Dongcheng Pharmaceutical Gets Nod to Trial Tumor Drug in China MT
Yantai Dongcheng Pharmaceutical's Unit Ties Up With Chinese Physics Institute for Electron Accelerator Development MT
Yantai Dongcheng Pharma Gets Nod to Trial Prostate Cancer Treatment in China MT
Dongcheng Pharma Forms Medical Isotopes JV With Germany’s Eckert & Ziegler MT
Qi Kang Medical Technology Co., Ltd. announced that it has received ?20 million in funding from Yantai Dongcheng Pharmaceutical Group Co.,Ltd. CI
Dongcheng Biochemicals Unit Gets Nod to Trial Prostate Cancer Drug in Singapore MT
Dongcheng Biochemicals' Unit Gets Nod to Market Dalteparin Sodium Injection MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Dongcheng Biochemicals Receives Good Manufacturing Practice Certificate from Germany MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Yantai Dongcheng Pharma Registers Raw Material For Deep Vein Thrombosis Drug MT
Yantai Dongcheng Pharma Registers Deep Vein Thrombosis Drug MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 10 July 2023 CI
Dongcheng Pharma Unit Gets Production License for Two Production Centers MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for 2022 CI
Dongcheng Pharma's Unit Passes GMP Inspection MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Yantai Dongcheng Pharma Unit Wins FDA Nod to Trial Prostate Cancer Drug MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
More charts
Yantai Dongcheng Biochemicals Co., Ltd is a China-based company principally engaged in the research, development, manufacture and sales of medical drugs. The Company’s main products are categorized into active pharmaceutical ingredients (APIs), nuclear medicines, chemical drugs and traditional Chinese medicines, which include heparin sodium APIs, chondroitin sulfate, preparation products, radionuclide drugs and others. The Company distributes its products in domestic market and to overseas markets.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.31 CNY
Average target price
20.3 CNY
Spread / Average Target
+52.52%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002675 Stock
  4. News Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
  5. Yantai Dongcheng Pharma Unit Secures License for Radioactive Cargo Transport